Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 Cases (1989-1999)

Antony S. Moore, Richard W Nelson, Carolyn J. Henry, Kenneth M. Rassnick, Orna Kristal, Gregory K. Ogilvie, Peter Kintzer

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective - To determine toxic effects of streptozocin given in combination with a diuresis protocol in dogs and establish whether streptozocin is efficacious in treatment of pancreatic islet cell tumors in dogs. Design - Retrospective study. Animals - 17 dogs. Procedure - Medical records were reviewed to obtain information regarding signalment, tumor stage and staging tests performed, number of streptozocin treatments, adverse effects, results of biochemical and hematologic monitoring during streptozocin treatment, tumor dimensions, duration of normoglycemia, and date of death, when applicable. Dogs were compared with a historical control group of 15 dogs treated surgically and medically. Results - 58 treatments were administered to the 17 dogs. Only 1 dog developed azotemia. Serum alanine aminotransferase activity increased in some dogs but decreased when treatment was discontinued. Hematologic toxicoses were rare. Vomiting during administration was uncommon but occasionally severe. Two dogs developed diabetes mellitus after receiving 5 doses. Median duration of normoglycemia for 14 dogs with stage-II or-III insulinoma treated with streptozocin was 163 days (95% confidence interval, 16 to 309 days), which was not significantly different from that for the control dogs (90 days; 95% confidence interval, 0 to 426 days). Two dogs had rapid resolution of paraneoplastic peripheral neuropathy, and 2 others had measurable reductions in tumor size. Conclusions and Clinical Relevance - Results suggest that streptozocin can be administered safely to dogs at a dosage of 500 mg/m2, IV, every 3 weeks when combined with a protocol for induction of diuresis and may be efficacious in the treatment of dogs with metastatic pancreatic islet cell tumors.

Original languageEnglish (US)
Pages (from-to)811-818
Number of pages8
JournalJournal of the American Veterinary Medical Association
Volume221
Issue number6
StatePublished - Sep 15 2002

Fingerprint

streptozotocin
islets of Langerhans
Streptozocin
Dogs
neoplasms
dogs
diuresis
Diuresis
Pancreatic islet cell tumors
confidence interval
Paraneoplastic Polyneuropathy
Confidence Intervals
Azotemia
Insulinoma
uremia
duration
peripheral nervous system diseases
Neoplasm Staging
Poisons
vomiting

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Moore, A. S., Nelson, R. W., Henry, C. J., Rassnick, K. M., Kristal, O., Ogilvie, G. K., & Kintzer, P. (2002). Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 Cases (1989-1999). Journal of the American Veterinary Medical Association, 221(6), 811-818.

Streptozocin for treatment of pancreatic islet cell tumors in dogs : 17 Cases (1989-1999). / Moore, Antony S.; Nelson, Richard W; Henry, Carolyn J.; Rassnick, Kenneth M.; Kristal, Orna; Ogilvie, Gregory K.; Kintzer, Peter.

In: Journal of the American Veterinary Medical Association, Vol. 221, No. 6, 15.09.2002, p. 811-818.

Research output: Contribution to journalArticle

Moore, AS, Nelson, RW, Henry, CJ, Rassnick, KM, Kristal, O, Ogilvie, GK & Kintzer, P 2002, 'Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 Cases (1989-1999)', Journal of the American Veterinary Medical Association, vol. 221, no. 6, pp. 811-818.
Moore, Antony S. ; Nelson, Richard W ; Henry, Carolyn J. ; Rassnick, Kenneth M. ; Kristal, Orna ; Ogilvie, Gregory K. ; Kintzer, Peter. / Streptozocin for treatment of pancreatic islet cell tumors in dogs : 17 Cases (1989-1999). In: Journal of the American Veterinary Medical Association. 2002 ; Vol. 221, No. 6. pp. 811-818.
@article{6441c8864cf44e23a6f72d887e7241a1,
title = "Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 Cases (1989-1999)",
abstract = "Objective - To determine toxic effects of streptozocin given in combination with a diuresis protocol in dogs and establish whether streptozocin is efficacious in treatment of pancreatic islet cell tumors in dogs. Design - Retrospective study. Animals - 17 dogs. Procedure - Medical records were reviewed to obtain information regarding signalment, tumor stage and staging tests performed, number of streptozocin treatments, adverse effects, results of biochemical and hematologic monitoring during streptozocin treatment, tumor dimensions, duration of normoglycemia, and date of death, when applicable. Dogs were compared with a historical control group of 15 dogs treated surgically and medically. Results - 58 treatments were administered to the 17 dogs. Only 1 dog developed azotemia. Serum alanine aminotransferase activity increased in some dogs but decreased when treatment was discontinued. Hematologic toxicoses were rare. Vomiting during administration was uncommon but occasionally severe. Two dogs developed diabetes mellitus after receiving 5 doses. Median duration of normoglycemia for 14 dogs with stage-II or-III insulinoma treated with streptozocin was 163 days (95{\%} confidence interval, 16 to 309 days), which was not significantly different from that for the control dogs (90 days; 95{\%} confidence interval, 0 to 426 days). Two dogs had rapid resolution of paraneoplastic peripheral neuropathy, and 2 others had measurable reductions in tumor size. Conclusions and Clinical Relevance - Results suggest that streptozocin can be administered safely to dogs at a dosage of 500 mg/m2, IV, every 3 weeks when combined with a protocol for induction of diuresis and may be efficacious in the treatment of dogs with metastatic pancreatic islet cell tumors.",
author = "Moore, {Antony S.} and Nelson, {Richard W} and Henry, {Carolyn J.} and Rassnick, {Kenneth M.} and Orna Kristal and Ogilvie, {Gregory K.} and Peter Kintzer",
year = "2002",
month = "9",
day = "15",
language = "English (US)",
volume = "221",
pages = "811--818",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "6",

}

TY - JOUR

T1 - Streptozocin for treatment of pancreatic islet cell tumors in dogs

T2 - 17 Cases (1989-1999)

AU - Moore, Antony S.

AU - Nelson, Richard W

AU - Henry, Carolyn J.

AU - Rassnick, Kenneth M.

AU - Kristal, Orna

AU - Ogilvie, Gregory K.

AU - Kintzer, Peter

PY - 2002/9/15

Y1 - 2002/9/15

N2 - Objective - To determine toxic effects of streptozocin given in combination with a diuresis protocol in dogs and establish whether streptozocin is efficacious in treatment of pancreatic islet cell tumors in dogs. Design - Retrospective study. Animals - 17 dogs. Procedure - Medical records were reviewed to obtain information regarding signalment, tumor stage and staging tests performed, number of streptozocin treatments, adverse effects, results of biochemical and hematologic monitoring during streptozocin treatment, tumor dimensions, duration of normoglycemia, and date of death, when applicable. Dogs were compared with a historical control group of 15 dogs treated surgically and medically. Results - 58 treatments were administered to the 17 dogs. Only 1 dog developed azotemia. Serum alanine aminotransferase activity increased in some dogs but decreased when treatment was discontinued. Hematologic toxicoses were rare. Vomiting during administration was uncommon but occasionally severe. Two dogs developed diabetes mellitus after receiving 5 doses. Median duration of normoglycemia for 14 dogs with stage-II or-III insulinoma treated with streptozocin was 163 days (95% confidence interval, 16 to 309 days), which was not significantly different from that for the control dogs (90 days; 95% confidence interval, 0 to 426 days). Two dogs had rapid resolution of paraneoplastic peripheral neuropathy, and 2 others had measurable reductions in tumor size. Conclusions and Clinical Relevance - Results suggest that streptozocin can be administered safely to dogs at a dosage of 500 mg/m2, IV, every 3 weeks when combined with a protocol for induction of diuresis and may be efficacious in the treatment of dogs with metastatic pancreatic islet cell tumors.

AB - Objective - To determine toxic effects of streptozocin given in combination with a diuresis protocol in dogs and establish whether streptozocin is efficacious in treatment of pancreatic islet cell tumors in dogs. Design - Retrospective study. Animals - 17 dogs. Procedure - Medical records were reviewed to obtain information regarding signalment, tumor stage and staging tests performed, number of streptozocin treatments, adverse effects, results of biochemical and hematologic monitoring during streptozocin treatment, tumor dimensions, duration of normoglycemia, and date of death, when applicable. Dogs were compared with a historical control group of 15 dogs treated surgically and medically. Results - 58 treatments were administered to the 17 dogs. Only 1 dog developed azotemia. Serum alanine aminotransferase activity increased in some dogs but decreased when treatment was discontinued. Hematologic toxicoses were rare. Vomiting during administration was uncommon but occasionally severe. Two dogs developed diabetes mellitus after receiving 5 doses. Median duration of normoglycemia for 14 dogs with stage-II or-III insulinoma treated with streptozocin was 163 days (95% confidence interval, 16 to 309 days), which was not significantly different from that for the control dogs (90 days; 95% confidence interval, 0 to 426 days). Two dogs had rapid resolution of paraneoplastic peripheral neuropathy, and 2 others had measurable reductions in tumor size. Conclusions and Clinical Relevance - Results suggest that streptozocin can be administered safely to dogs at a dosage of 500 mg/m2, IV, every 3 weeks when combined with a protocol for induction of diuresis and may be efficacious in the treatment of dogs with metastatic pancreatic islet cell tumors.

UR - http://www.scopus.com/inward/record.url?scp=0037105752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037105752&partnerID=8YFLogxK

M3 - Article

C2 - 12322919

AN - SCOPUS:0037105752

VL - 221

SP - 811

EP - 818

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 6

ER -